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Bacillus anthracis, the etiological agent of anthrax, is a spore-forming Gram-positive bacterium. Infection with this
pathogen results in multisystem dysfunction and death. The pathogenicity of B. anthracis is due to the production of
virulence factors, including edema toxin (ET). Recently, we established the protective role of type-IIA secreted
phospholipase A2 (sPLA2-IIA) against B. anthracis. A component of innate immunity produced by alveolar
macrophages (AMs), sPLA2-IIA is found in human and animal bronchoalveolar lavages at sufficient levels to kill B.
anthracis. However, pulmonary anthrax is almost always fatal, suggesting the potential impairment of sPLA2-IIA
synthesis and/or action by B. anthracis factors. We investigated the effect of purified ET and ET-deficient B. anthracis
strains on sPLA2-IIA expression in primary guinea pig AMs. We report that ET inhibits sPLA2-IIA expression in AMs at
the transcriptional level via a cAMP/protein kinase A–dependent process. Moreover, we show that live B. anthracis
strains expressing functional ET inhibit sPLA2-IIA expression, whereas ET-deficient strains induced this expression. This
stimulatory effect, mediated partly by the cell wall peptidoglycan, can be counterbalanced by ET. We conclude that B.
anthracis down-regulates sPLA2-IIA expression in AMs through a process involving ET. Our study, therefore, describes
a new molecular mechanism implemented by B. anthracis to escape innate host defense. These pioneering data will
provide new molecular targets for future intervention against this deathly pathogen.
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Introduction
Bacillus anthracis, the etiological agent of anthrax, is a spore-
forming Gram-positive bacterium [1]. Even though anthrax is
primarily a disease of herbivores, all mammals are susceptible
to B. anthracis infection. Human infection can occur via
cutaneous, gastrointestinal, or respiratory routes, either
accidentally or intentionally as a potential consequence of a
bioweapon or a terrorism threat. Whatever the infection
route used by this bacterium, spores are taken up by
macrophages and/or dendritic cells, and subsequently migrate
and germinate in the draining lymph nodes [2,3]. The
infection then spreads through the whole organism, leading
to respiratory failure and multiple hemorrhagic lesions.
Despite appropriate therapy, all these forms of infection
may progress to fatal systemic anthrax, which is characterized
by shock-like symptoms, sepsis, and respiratory failure [4].
Pulmonary infection by B. anthracis has been shown to be the
most life-threatening form of the disease, causing a near
100% mortality.
Innate immune response is the ﬁrst line of host defense
against invading pathogens. Type-IIA secreted phospholipase
A2 (sPLA2-IIA) [5,6] is one of the major components involved
in innate host defense against bacteria [7,8]. This enzyme
belongs to a family of enzymes catalyzing the hydrolysis of
phospholipids at the sn-2 position, leading to the generation
of lysophospholipids and free fatty acids [5,6]. sPLA2-IIA is
produced by several cell types, including guinea pig alveolar
macrophages (AMs) [9], which play a central role in innate
immunity and are the ﬁrst line of defense against inhaled
pathogens. These cells are the major pulmonary source of
sPLA2-IIA in experimental models of acute lung injury [9,10].
Besides its ability to hydrolyze pulmonary surfactant phos-
pholipids [11] and release arachidonic acid [12], sPLA2-IIA
exhibits potent bactericidal activity, especially against Gram-
positive bacteria [13–15]. The bactericidal activity is exhibited
through a process involving rapid hydrolysis of bacterial
membrane phospholipids [16,17]. This activity is the most
signiﬁcant biological property of sPLA2-IIA, being observed
at much lower concentrations of this enzyme than for other
properties. sPLA2-IIA is constitutively present in guinea pig
airways at concentrations [11] above those required for
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guinea pig AMs constitutively release enough sPLA2-IIA to
kill B. anthracis [17]. sPLA2-IIA is highly bactericidal for B.
anthracis, either in vitro or in vivo [17,18]. This anthracidal
effect occurs both against germinated spores and bacilli. A
sPLA2-IIA–dependent anthracidal activity was found in
human bronchoalveolar lavage ﬂuids (BALF) of patients with
acute respiratory distress syndrome [17]. In a more recent
study, we showed that transgenic mice expressing sPLA2-IIA
are resistant to experimental infection with B. anthracis,i n
contrast to sPLA2-IIA
 /  mice [18]. Interestingly, treating
sPLA2-IIA
 /  mice with recombinant sPLA2-IIA protected
them against mortality caused by B. anthracis infection.
The exact mechanisms by which B. anthracis induces
anthrax are not fully understood; however, it is clearly
established that this bacterium spreads rapidly in the host at
the early stages of infection without a detectable immune
response [2,19,20]. This allows bacteria to replicate to very
high numbers in the blood, ultimately leading to death of the
host [4]. This is due to the ability of B. anthracis to subvert the
host immune response [19,20] by the action of B. anthracis
toxins. Indeed, B. anthracis secretes a binary A-B toxin
composed of a single B transporter called protective antigen
(PA) and two alternative A components, lethal factor (LF) or
edema factor (EF) [1,19]. LF and EF act in pairs, with PA
leading to lethal toxin (LT¼PAþLF) and edema toxin (ET¼
PA þ EF), respectively. PA serves as a transporter delivering
LF and EF inside host cell cytosol where they act on speciﬁc
molecular targets. EF is a calmodulin-activated adenyl-cyclase
(AC) leading to a sustained increase in cAMP levels [21].
However, little is known about the genes targeted by ET and
their implication in the pathogenesis of anthrax.
Here, we report that ET inhibits sPLA2-IIA expression in
AMs and demonstrate that this inhibition occurs through the
sequential accumulation of cAMP and stimulation of protein
kinase A (PKA) activity. In the absence of ET, B. anthracis was
able to induce sPLA2-IIA expression via a process at least
partly involving the cell wall component, peptidoglycan (PG).
ET also stopped this induction. This study is important
because AMs are a major source of sPLA2-IIA, a critical
component in host defense against B. anthracis. Inhibition of
sPLA2-IIA expression in AMs by ET may represent an
effective strategy for subverting pulmonary host immune
response by B. anthracis.
Results
ET Impairs Lipopolysaccharide-Induced sPLA2-IIA
Expression, but Not Interleukin 8 and Prostaglandin E2
Production, and Nuclear Factor j B Translocation
AMs were preincubated with ET (PA þ EF) 1 h before
adding lipopolysaccharide (LPS) to analyze the effect of ET
on sPLA2-IIA expression. ET stopped both basal and LPS-
induced sPLA2-IIA secretion in a concentration-dependent
manner (Figure 1A). No effect was observed when EF or PA
was added separately to AMs (unpublished data). Inhibition of
sPLA2-IIA secretion by ET was also observed when AMs were
stimulated by tumor necrosis factor-a (TNFa) instead of LPS
(Figure 1B). We showed that LPS induced a marked increase
in sPLA2-IIA mRNA levels, and that the increase was
subsequently abolished by the addition of ET (Figure 1C).
We next investigated the effect of ET on two other
inﬂammatory mediators produced by AMs, interleukin 8
(IL-8) and prostaglandin E2 (PGE2). ET failed to interfere
with LPS-induced IL-8 (Figure 1D) and PGE2 (Figure 1E)
secretion. We also examined the effect of ET on nuclear
factor j B (NF-jB) translocation. ET had no effect on LPS-
induced NF-jB translocation (Figure 1F), as assessed by
electrophoretic mobility shift assay (EMSA). These results
together indicated that ET inhibits sPLA2-IIA expression in
AMs through a different signaling pathway from those
inducing IL-8 and PGE2 secretion or NF-jB translocation.
ET Impairs sPLA2-IIA Expression via a cAMP/PKA-
Dependent Pathway
Because ET exhibits a calmodulin-dependant AC, we
examined its effect on intracellular cAMP levels in our cell
system. A 30-min incubation of AMs with ET led to an
increase in cAMP levels, whereas LPS had no effect (Figure
2A). The induction of cAMP accumulation by ET was
transient; cAMP levels returned to near basal levels after
AMs were incubated with ET for 24 h (Figure 2A, insert). In
agreement, a cAMP-elevating agent, forskolin, signiﬁcantly
inhibited LPS-induced sPLA2-IIA secretion (Figure 2B). AC
inhibitors (adefovir and ddA) reversed ET inhibition of LPS-
induced sPLA2-IIA secretion (Figure 2C).
cAMP is known to activate protein kinases, such as PKA;
thus, this kinase may be involved in the inhibition of sPLA2-
IIA expression by ET. ET induced a marked and transient
activation of PKA in AMs (Figure 2D). Indeed, this activation
was observed 2 h after adding ET, and was undetectable 20 h
later (unpublished data). To mimic the ET-induced PKA
activation, we examined the effect of 6-Bnz-AMP, a speciﬁc
agonist for PKA. 6-Bnz-AMP inhibited both basal and LPS-
induced sPLA2-IIA expression (Figure 2E). By contrast, O-
Me-cAMP, a speciﬁc agonist for the exchange protein directly
activated by cAMP (Epac) [22], had no effect on sPLA2-IIA
expression. Taken together, our results suggested that ET
inhibits LPS-induced sPLA2-IIA expression in AMs via a
cAMP/PKA-dependent process.
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Author Summary
All mammals are susceptible to infection by Bacillus anthracis, the
etiological agent of anthrax. Infection can occur either accidentally
or as a potential consequence of a terrorism threat. Pulmonary
infection is the most life-threatening form of the disease, causing a
near 100% mortality. Despite appropriate therapy, all forms of
infection may progress to fatal systemic anthrax, characterized by
sepsis and respiratory failure. Thus, it is important to understand the
mechanisms of host defense against B. anthracis.W eh a v e
previously shown that alveolar macrophages produce an enzyme
involved in innate defense that can kill B. anthracis: the enzyme is
known as secreted phospholipase A2-IIA (sPLA2-IIA). The alveolar
macrophage is one of the first cell types to come in contact with B.
anthracis. In this study, we show that live B. anthracis spores
stimulate the synthesis of sPLA2-IIA, this stimulation being counter-
balanced by the inhibitory effect of the edema toxin produced by
germinated spores and bacilli. Our study suggests that inhibition of
sPLA2-IIA synthesis by edema toxin is a mechanism by which B.
anthracis can escape innate host defense. These pioneering data
provide new molecular targets for future intervention against this
deadly pathogen.Effect of ET on CREB Activation
Because PKA is known to phosphorylate cAMP-responsive
element binding protein (CREB), we examined whether this
transcription factor mediates the inhibition of sPLA2-IIA
expression by ET. ET induced a time-dependent CREB
phosphorylation (Figure 3A), but had no effect on the total
level of CREB (Figure 3B) in AMs, as assessed by western blot
analysis. We also investigated the effects of ET on CREB
activation using Chinese hamster ovary (CHO) cells trans-
fected with a CREB ([CRE]4-Luc) reporter plasmid construct.
ET signiﬁcantly increased the CREB luciferase activity (Figure
3C). However, LPS had no effect on this activity and failed to
interfere with ET-induced CREB activation. This activation
was prevented by cotransfecting cells with a dominant-
negative CREB construct, pGR-CREBM1, as opposed to pGR
(Figure 3C). Transfection of CHO cells with a sPLA2-IIA
promoter luciferase construct demonstrated that ET inhibits
LPS-induced sPLA2-IIA gene transcription activity (Figure
Figure 1. ET Impairs LPS-Induced sPLA2-IIA Expression, but Not IL-8, PGE2, and NF-jB Translocation
(A) AMs were pretreated with ET (PAþEF) for 1 h before overnight stimulation with P. aeruginosa LPS (50 ng/ml). ET consisted of a fixed concentration
of PA (1 lg/ml) and increasing concentrations of EF.
(B) AMs were incubated with 1 lg/ml of ET (PA 1 lg/ml þ EF 1 lg/ml), and were then stimulated overnight with TNFa (500 ng/ml). The sPLA2-IIA
secretion levels were then assessed, as detailed in the Materials and Methods.
(C–E) After 1-h pretreatment with 1 lg/ml of ET (PA 1 lg/mlþEF 1 lg/ml), followed by an overnight stimulation with LPS (50 ng/ml), sPLA2-IIA mRNA
levels and IL-8 and PGE2 concentrations were measured in culture medium. (C) shows reverse-transcription PCR (RT-PCR) analysis of sPLA2-IIA mRNA
expression of extracts from three independent experiments; (D) and (E) show IL-8 and PGE2 concentrations, respectively.
(F) AMs were incubated with ET for 1 h and then were stimulated with LPS. After a 2-h incubation, NF-jB translocation was measured by EMSA.
The data are the mean 6 standard error of the mean (SEM), and are representative of four separate experiments. An asterisk (*) indicates p , 0.05.
doi:10.1371/journal.ppat.0030187.g001
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Subversion of Innate Defense by AnthraxFigure 2. ET Impairs sPLA2-IIA Expression via a cAMP/PKA-Dependent-Pathway
(A) AMs were treated with ET (1 lg/ml) and were then stimulated by LPS (50 ng/ml). After 30-min or 24-h (insert) incubation, cell lysates were collected
and cAMP concentrations were measured by enzyme immunoassay (EIA) and expressed in picomoles per milligram of protein. NS, not stimulated.
(B) AMs were treated with forskolin (FK; 20 lM) followed by LPS incubation.
(C) Reversal of ET-mediated inhibition of sPLA2-IIA secretion by ET inhibitors. AMs were treated with adefovir (10 lM) for 5 h and incubated with ET (1
lg /ml) for 1 h. In a separate assay, ET (1 lg/ml) was treated with 100 lM ddA for 1 h and incubated with AMs for an additional 1 h. AMs were then
stimulated with LPS (50 ng/ml) overnight, and supernatants were collected to measure sPLA2-IIA secretion.
(D) After 2-h incubation, cell lysates were collected, and PKA activity was measured.
(E) AMs were treated with 6-Bnz-cAMP or O-Me-cAMP (200 lM) for 1 h before overnight LPS stimulation.
The data are the mean 6 SEM and are representative of three separate experiments. An asterisk (*) indicates p ,0.05.
doi:10.1371/journal.ppat.0030187.g002
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Subversion of Innate Defense by Anthrax3D). Similar results were observed when LPS was replaced by
IL-1b as the inducer of sPLA2-IIA expression (unpublished
data). However, cotransfection of a dominant-negative CREB
construct failed to reverse the inhibition of sPLA2-IIA gene
transcription activity (Figure 3D), indicating that CREB does
not mediate ET inhibition of sPLA2-IIA expression.
Infection of AMs with Live B. anthracis Modulates sPLA2-
IIA Expression
Using a more pathophysiological approach, we examined
whether infecting AMs with B. anthracis bacilli modulates
sPLA2-IIA expression and whether ET participates in this
modulation. AMs were incubated in an antibiotic-free culture
medium for 3 h with either RP10 or RPLC2 bacilli; RP10
produces functional and RPLC2 produces inactive ET. After
removing bacilli not having undergone phagocytosis, AMs
were stimulated overnight with LPS in culture medium
supplemented with antibiotics. The RP10 strain inhibited
LPS-stimulated sPLA2-IIA secretion, whereas the RPLC2
strain had no effect (Figure 4A). Inhibition by the RP10
strain occurred in a multiplicity of infection (MOI)-depend-
ent manner and was selective for sPLA2-IIA. Indeed, this
strain failed to inhibit LPS-induced PGE2 (Figure 4B) and IL-
8 (Figure 4C) production. These ﬁndings demonstrated that
in LPS-stimulated AMs, B. anthracis strains producing func-
tionally active ET down-regulated sPLA2-IIA expression.
We next examined the effect of B. anthracis on sPLA2-IIA
expression in unstimulated AMs. RPLC2 bacilli induced
Figure 3. ET Induces CREB Activation
AMs were incubated for 2 h with ET (1 lg/ml) and were then stimulated by LPS (50 ng/ml). After incubation for the time periods indicated, total cell
proteins were extracted.
(A and B) Western blot analyzes were then performed using phospho-CREB (ser 133) (A) or CREB (B) antibodies. The figure also shows the
phosphorylation (A) and expression (B) levels of the activating transcription factor-1 (ATF-1). Corresponding quantifications were carried out using
densitometry and were expressed as arbitrary units (representative of three separate experiments).
(C) CHO cells were transfected with CREB ([CRE]4-Luc) reporter plasmid and/or dominant-negative CREB construct (pGR-CREBM1) or vehicle (pGR) for 24
h, pretreated for 1 h with ET (1 lg/ml) and stimulated with LPS (50 ng/ml) for an additional 24 h.
(D) CHO cells were transfected with the sPLA2-IIA-Luc reporter plasmid and/or pGR-CREBM1. After 24-h transfection, cells were pretreated for 1 h with
ET (1 lg/ml) and were stimulated with LPS (50 ng/ml) for an additional 24 h. Cells were then lysed, and the luciferase activity was measured and
normalized with b-galactosidase activity.
The data are the mean 6 SEM and are representative of four separate experiments. An asterisk (*) indicates p , 0.05 ; a hash mark (#) indicates p , 0.05
compared to corresponding pGR controls.
doi:10.1371/journal.ppat.0030187.g003
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Subversion of Innate Defense by AnthraxFigure 4. Infection of AMs with B. anthracis Inhibits sPLA2-IIA Secretion, but Not IL-8 or PGE2 Release
(A–C) AMs were infected with B. anthracis (RP10 and RPLC2 strains) at the indicated MOI for 3 h in the absence of antibiotics. Cells were then washed
and incubated overnight in RPMI 1640 supplemented with 3% FCS and antibiotics, in the presence or absence of LPS (50 ng/ml). Supernatants were
collected, and sPLA2-IIA secretion and PGE2 and IL-8 concentrations were measured. Effects of bacilli on sPLA2-IIA secretion (A) and PGE2 (B) and IL-8
(C) production in LPS-stimulated AMs.
(D and E) Effect of bacilli (MOI 20:1) on sPLA2-IIA secretion (D), and PGE2 (E) and IL-8 (F) production in unstimulated AMs. NS, not stimulated.
(G) Effect of spores and bacilli (MOI 20:1) on sPLA2-IIA secretion (G) in unstimulated AMs.
(H and I) Effect of Cyto D on the modulation of sPLA2-IIA expression by RP10 spores (H) and bacilli (I). AMs were incubated with 3 lM Cyto D for 30 min
before addition of bacteria (MOI 20:1). AMs were washed 3 h later and incubated in the presence (I) or absence (H) of LPS.
The data are the mean 6 SEM and are representative of four separate experiments. An asterisk (*) indicates p , 0.05.
doi:10.1371/journal.ppat.0030187.g004
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Subversion of Innate Defense by AnthraxsPLA2-IIA expression (Figure 4D), and PGE2 (Figure 4E) and
IL-8 (Figure 4F) secretion. The RP10 bacilli strain induced
PGE2 and IL-8 secretion, but had no effect on sPLA2-IIA
expression (Figure 4D–4F). Interestingly, RP10 and RPLC2
spores induced sPLA2-IIA expression, even after 3 h of
infection (Figure 4G). These ﬁndings indicate that in the
sporular state, RP10 and RPCL2 strains induce sPLA2-IIA
expression. However, in the bacilli state, the RPCL2 strain
(devoid of ET) induced sPLA2-IIA expression, whereas the
RP10 strain (producing ET) exerted an inhibitory effect. AMs
were incubated with cytochalasin D (Cyto D) before adding
the RP10 strain, to examine the impact of B. anthracis
phagocytosis on sPLA2-IIA expression. Cyto D reduced the
inhibitory effect of bacilli on sPLA2-IIA expression, but failed
to interfere with the stimulatory effect of spores (Figure 4H
and 4I). This suggests that both extracellular and intracellular
bacilli are involved in inhibiting sPLA2-IIA expression,
whereas extracellular spores seem to play a more important
role in inducing this enzyme.
B. anthracis Peptidoglycan Induces sPLA2-IIA Expression
That Is Inhibited by ET
As RPLC2 strain induces sPLA2-IIA expression in AMs, we
searched for which B. anthracis component was involved in
this induction. PG puriﬁed from B. anthracis stimulated
sPLA2-IIA expression (Figure 5A). PG, as well as LPS, induced
NF-jB translocation, as assessed by EMSA (Figure 5B). PG-
induced sPLA2-IIA expression was abolished if AMs were
pretreated with the NF-jB inhibitor CAPE (Figure 5C).
Interestingly, pretreating AMs with ET stopped sPLA2-IIA
expression induced by B. anthracis PG (Figure 5D). PG-
induced sPLA2-IIA expression was also inhibited by the
cAMP-elevating agent, forskolin, and the PKA agonist, 6-Bnz-
cAMP (Figure 5E).
Figure 5. B. anthracis PG Induces sPLA2-IIA Expression
(A) After AMs were stimulated overnight with the indicated concentrations of PG, sPLA2-IIA secretion was examined.
(B) After a 1-h incubation with PG (500 ng/ml) or LPS (50 ng/ml), the nuclear extracts were obtained and EMSA was performed. NS, not stimulated.
(C) AMs were incubated for 1 h with CAPE (10 lM), followed by an overnight stimulation with PG (500 ng/ml).
(D) AMs were pretreated with 6-Bnz-cAMP (200 lM), FK (20 lM), or ET (1 lg/ml) for 1 h before overnight stimulation with B. anthracis PG (2 lg/ml).
Then, the supernatants were collected to measure sPLA2-IIA secretion.
The data are the mean 6 SEM and are representative of four experiments. An asterisk (*) indicates p , 0.05.
doi:10.1371/journal.ppat.0030187.g005
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In this study, we investigated the effect of B. anthracis, the
causative agent of anthrax [1–4], on the expression of sPLA2-
IIA, an important component of host defense against
invading bacteria. This enzyme is bactericidal in vitro or in
vivo, and is especially active against Gram-positive bacteria,
including B. anthracis [7,8,17,18]. sPLA2-IIA is produced by
AMs and found in human and animal BALF at sufﬁcient levels
to kill B. anthracis [17]; these ﬁndings are consistent with the
enzyme having a role in host defense against pulmonary
anthrax. However, despite the ability of lungs to produce
sPLA2-IIA, the pulmonary form of anthrax has been shown to
be fatal, causing almost 100% mortality [1–4]. This led us to
postulate that B. anthracis may inhibit sPLA2-IIA synthesis by
AMs, subvert host pulmonary defense, and allow this
pathogen to spread extensively in the host.
We show here that ET inhibits sPLA2-IIA secretion by AMs,
interfering with its expression at the transcriptional level.
Inhibiting sPLA2-IIA secretion may decrease the capacity of
AMs to kill B. anthracis bacilli and germinated spores. Indeed,
AM activity against B. anthracis has been shown to be at least
partly associated with sPLA2-IIA, as it was reduced by an
sPLA2-IIA inhibitor [17]. This inhibition was observed what-
ever the stimuli used (LPS, TNFa , IL1b, or PG). We analyzed
the signaling pathways by which ET down-regulates sPLA2-
IIA expression; our analysis suggested that this inhibition
occurs via a process involving cAMP accumulation. Our
studies showed that this accumulation was transient, reaching
near basal values within 24 h. This contrasts with previous
studies reporting that cAMP accumulation was elevated for
48 h or more after ET incubation with NIH/3T3 ﬁbroblasts
and RAW 267 macrophages [23]. Thus, it is likely that the
duration and amplitude of cAMP accumulation induced by
ET may vary with the cell type considered. Because cAMP
activates several kinases, we examined whether PKA and
Epac, two cAMP-dependent kinases, were involved in this
process. PKA but not Epac, appeared to mediate ET-induced
inhibition of sPLA2-IIA expression. Our results also sug-
gested that elevating intracellular cAMP concentrations
(either by ET or 6-Bnz-cAMP) interfered with basal and
LPS-induced sPLA2-IIA expression by different mechanisms.
The inhibition of induced expression appeared to occur
through a process that interferes, at least partly, with the
sPLA2-IIA promoter, whereas the inhibition of basal ex-
pression appeared to be independent of the sPLA2-IIA
transcription.
PKA phosphorylates proteins, such as CREB, that are
involved in regulating gene expression in mammalian cells
[24]. This factor can modulate, either positively or negatively,
gene expression in several cell-activation processes [24,25].
Although ET induces CREB activation, this transcription
factor does not mediate the inhibition of sPLA2-IIA
expression by ET. However, it is likely that CREB activation
by ET could modulate the expression of other genes involved
in host defense, which remain to be identiﬁed. We next
investigated whether ET inhibits sPLA2-IIA expression by
interfering with the activation of NF-jB, known to be critical
in inducing sPLA2-IIA expression [26]. ET had no effect on
stimulated NF-jB translocation in AMs. Also, ET had no
effect on the secretion of IL-8, whose expression is controlled
by NF-jB. However, we cannot exclude that ET may interfere
with stimulating cofactors involved in NF-jB coactivation at
the sPLA2-IIA promoter level. Studies in progress in our
laboratory showed that trichostatin A, an inhibitor of histone
deacetylase (HDAC) activity [27], signiﬁcantly decreased
sPLA2-IIA expression in LPS-stimulated AMs. Because HDAC
activity is altered by a PKA-dependent phosphorylation [28],
it is likely that HDAC may play a role in the inhibition of
sPLA2-IIA expression by ET. Further studies are required to
verify this hypothesis.
In a more physiological approach, we investigated whether
ET modulates sPLA2-IIA expression during infection of AMs
with live B. anthracis. This bacterium inhibits LPS-induced
sPLA2-IIA expression via ET. Indeed, RPLC2, the bacterial
mutant with inactive ET, had no effect on this induction,
whereas the RP10 strain expressing functional ET abolished
LPS-induced sPLA2-IIA expression. Incubating RPLC2 bacil-
li, which produce inactive ET, with unstimulated AMs
induced sPLA2-IIA expression. This suggested the existence
of bacterial component(s) that are able to induce sPLA2-IIA
synthesis, and that their actions are masked by the ET
inhibitory effect produced by RP10 bacilli. Our ﬁndings
showed that the cell wall PG puriﬁed from B. anthracis induces
sPLA2-IIA expression via a process involving NF-jB activa-
tion. It is still not clear whether PG-induced sPLA2-IIA
expression occurs via an activation of TLR2 or Nod, two PG
recognition proteins [29]. A recent study has reported that
Nod may be involved in cell activation by B. anthracis spores
[ 3 0 ] .W ec a n n o te x c l u d e ,h o w e v e r ,t h a to t h e rb a c t e r i a l
components present in the cell wall or released by B. anthracis
may also be involved in inducing sPLA2-IIA expression.
Interestingly, ET suppressed PG-induced sPLA2-IIA expres-
sion, conﬁrming the relevance of our studies, and showing
that ET also suppresses the sPLA2-IIA expression induced by
B. anthracis itself. Therefore, during host infection, B. anthracis
may modulate sPLA2-IIA expression, either positively or
negatively, depending on the status of ET synthesis in the
bacterium (Figure 6).
Mammalian pulmonary infection with B. anthracis is
initiated by the inhalation of spores, the cell walls of which
contain PG. Infecting spores therefore induce sPLA2-IIA
expression in the earlier stages of infection. This is consistent
with previous studies, which have reported that B. anthracis
spores stimulate cytokine production in various cells [31–33].
The susceptibility of inhaled spores to the bactericidal
activity of sPLA2-IIA present in airways is dependent on
their germination velocity; this is because sPLA2-IIA only kills
germinated spores and bacilli [17]. Previous in vivo studies [3]
have shown that germination occurred rapidly upon entry
into the lung (35–60 min), and that the spores were mostly
found inside the AM. This was followed by a rapid onset (,3
h) of expression of genes encoding virulence factors, such as
LF, PA, and EF [34]. Elimination of inhaled B. anthracis by the
host would thus depend on the balance between sPLA2-IIA
levels in the airways and bacterial load. If the balance favors
sPLA2-IIA, germinated spores and bacilli would be killed
quickly. Our previous studies have shown that the constitu-
tive (basal) levels of sPLA2-IIA present in guinea pig airways
[11] are greater than those required for killing B. anthracis
[17], and that these levels were greater in inﬂamed lungs [11].
sPLA2-IIA was also found in BALF of patients with lung
inﬂammatory diseases (ARDS) at sufﬁcient levels to exert this
anthracidal effect. However, it is still unknown whether BALF
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of sPLA2-IIA, and whether this enzyme would be available
soon after the invasion of inhaled spores. It is also possible
that some germinated bacteria may escape killing by sPLA2-
IIA. Therefore, bacilli derived from geminated spores rapidly
produce ET, which may in turn inhibit sPLA2-IIA expression
and shift the balance in favor of bacteria. In vivo studies, in
which guinea pigs are infected with inhaled B. anthracis
spores, are required to investigate this possibility.
Our previous studies clearly established a role for sPLA2-
IIA in host defense against B. anthracis; however, it is still
unknown whether this enzyme participates in killing germi-
nated spores previously ingested by AMs. sPLA2-IIA is
involved in the killing of Staphylococcus aureus ingested by
neutrophils [35]. Indeed, added sPLA2-IIA binds to S. aureus
before its internalization by neutrophils and participates in
the cytotoxicity of these cells towards ingested bacteria.
Therefore, we suggest that sPLA2-IIA is involved in killing B.
anthracis ingested by AMs.
In conclusion, we report here that B. anthracis represses the
expression of sPLA2-IIA, a major component in innate host
response with anthracidal properties, in AMs. This inhibition
occurs through a process involving ET-mediated cAMP
accumulation and PKA activation, and represents a novel
mechanism for evading the innate immune response of the
host. Other bacteria (for example Bordetella pertussis or Yersinia
pestis) [19] are known to produce toxins with AC activity; thus,
we can speculate that the inhibition of sPLA2-IIA expression
in AMs may be a more general process occurring during
bacterial infection. Therefore, using pharmacological ap-
proaches to inhibit ACs of invading bacteria may represent a
therapeutic strategy for treating not only pulmonary anthrax,
but also other bacterial pulmonary infections.
Materials and Methods
Animals and reagents. Male Hartley guinea pigs were purchased
from Charles River Laboratories. RPMI 1640 cell culture medium was
purchased from Invitrogen, and fetal calf serum (FCS) from Hyclone.
Caffeic acid phenethyl ester (CAPE), and cytochalasin D (Cyto D)
were purchased from Biomol. LPS from Pseudomonas aeruginosa and 29,
59-dideoxyadenosine 39-triphosphate (ddA) were purchased from
Sigma Aldrich. N
6-Benzoyladenosine-39,5 9-cyclic monophosphate (6-
Bnz-cAMP) and 8-(p-Chlorophenylthio)-29-O-methyl-adenosine-39,
59-cyclic monophosphate (O-Me-cAMP) were purchased from Biolog.
CREB and phospho-CREB antibodies were obtained from Cell
Signaling Technology. EF, PA, and PG from B. anthracis were
produced and puriﬁed as described previously [36]. BIS-POM-PMEA
(adefovir) was provided by Dr. W. J. Tang (University of Chicago,
Chicago, Illinois).
B. anthracis strains. The following isogenic B. anthracis strains were
studied: (1) the single mutant RP10 Dlef producing only PA-EF and (2)
the double-mutant RPLC2 on lef and cya genes producing PA-LF and
PA-EF, respectively, without enzymatic functions [37].
Treatment of AMs with bacterial toxins and drugs. Guinea pig
bronchoalveolar lavages (BAL) were performed with PBS, and AMs
were isolated, as previously described [9]. AMs were then adjusted at
2.10
6 cells/ml in RPMI 1640 with 3% FCS and 1% of antibiotic, and
were pretreated with ET (PAþEF), 6-Bnz-cAMP, O-Me-cAMP, or TSA
1 h before incubation with LPS, PG, or TNFa. In certain experiments,
AMs were pretreated 5 h with adefovir before incubation with ET. In
other experiments, ET was preincubated with ddA for 1 h before
being added to AMs. These reagents were used at the concentrations
indicated in the ﬁgures. Subsequent analyzes were performed as
detailed below.
Infection of AMs. Cells were infected with B. anthracis bacilli or
spores for 3 h at various MOI values. Cells were then washed twice
and incubated overnight in RPMI 1640 supplemented with 3% FCS
and 2.5 lg/ml gentamicin in the presence or absence of LPS. In
certain experiments, AMs were pretreated with Cyto D for 30 min
before adding bacteria. At the end of the incubation, media were
harvested and centrifuged. The resulting supernatants were collected
and stored at  20 8C for subsequent analyzes.
RNA extraction and reverse-transcription PCR analysis. Cells were
grown on a cell culture plate and total RNA was extracted using an
RNeasy kit (Qiagen). DNase treatment was performed using 2 lgo f
extracted RNA, 1 ll of DNase I (Amersham Biosciences), and 0.5 llo f
RNasin (Promega) in a total volume of 20 ll in the manufacturer’s
buffer. cDNA were obtained by incubating RNA with 1 mM dNTP
(Eurobio), 1.5 ll of hexamers as primers, 20 units of RNasin
(Promega), and 300 units of Moloney murine leukemia virus reverse
transcriptase RNase H minus (Promega) in a total volume of 50 llo f
the manufacturer’s buffer; the incubation was for 1 h at 42 8C and was
followed by a 10-min incubation at 70 8C. PCR was performed using
speciﬁc primers (Proligo) for guinea pig sPLA2-IIA (sense, 59-ACA
AGT TAT GGC GCC TAT GG-39; antisense, 59-GCC CAG TGT AGC
TGT GAA GC-39). As an internal control, we used primers for the
detection of guinea pig b-actin (sense, 59-AAA CTG GAA CGG TGA
AGG TG-39; antisense, 59-TCA AGT TGG GGG ACA AAA AG-39).
Ampliﬁcations were performed in a Peltier thermal cycler (MJ
Research) using Q-BioTaq polymerase (Qbiogene). For the detection
of sPLA2-IIA, PCR thermo-cycling included 30 cycles of denaturation
at 95 8C for 45 s and annealing at 60 8C for 45 s.
Nuclear protein extraction and electrophoretic mobility shift
assays. Nuclear proteins were extracted from 2.10
6 AMs, as previously
Figure 6. A Schematic Model for the Modulation of sPLA2-IIA Expression
in AMs by B. anthracis
At the earlier stages of infection, PG constitutively present in B. anthracis
cell walls induces sPLA2-IIA and IL-8 expression via an NF-jB–dependent
process. After being taken up by AMs, B. anthracis spores undergo
germination, which subsequently leads to bacilli formation and ET
production. ET down-regulates sPLA2-IIA expression through sequential
cAMP accumulation and PKA activation. The mechanisms by which PKA
activation leads to down-regulation of sPLA2-IIA expression remains to
be elucidated. As sPLA2-IIA is involved in pulmonary host defense
against B. anthracis, its repression may lead to the proliferation of this
bacterium in lung tissues. The black arrows represent the stimulatory
pathway involving spores, and the red arrows correspond to the
inhibitory pathway involving bacilli. ET appears to inhibit basal
expression and induce sPLA2-IIA expression by various mechanisms
(for more detail, see Discussion).
IjB, inhibitor of j B.
doi:10.1371/journal.ppat.0030187.g006
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Cruz Biotechnology) corresponded to an NF-jBb i n d i n gs i t e
consensus sequence of 59-AGT TGA GGG GAC TTTT CCC AGG C-
39. The overhanging ends were c-
32P–labeled with T4 polynucleotide
kinase (Biolabs). Protein concentrations were determined using a
Nanodrop spectrophotometer (Nyxor Biotech). Binding reactions
were performed in a total volume of 20 ll for 20 min at room
temperature, by adding 5 lg of nuclear extract, 10 llo f2 3 binding
buffer (40 mM HEPES [pH 7], 140 mM KCl, 4 mM DTT, 0.02%
Nonidet P-40, 8% Ficoll, 200 lg/ml BSA, 1 lg of poly(dI:dC)), and 1 ll
of labeled probe. The reaction mixtures were separated on a 5%
polyacrylamide gel in 0.5% Tris/borate/EDTA buffer at 150 V for 2 h.
Gels were dried and exposed for 2 to 12 h. We have previously shown,
using supershift analysis, that antibodies directed against NF-jB’s p50
and p65 subunits displaced the NF-jB band in LPS-stimulated AMs;
this conﬁrmed that the observed complexes belong to the NF-jB
family [39].
Protein extraction and western blot analyzes. Proteins from AMs
were extracted in lysis buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM
EDTA, 100 lM leupeptin, 100 mM aprotinin, 1 mM soybean trypsin
inhibitor, 5 mM NEM, 1 mM PMSF, 5 mM benzamidine, and 1%
Triton W-100 [pH 7.4]) and were run on a gel under reducing
conditions. Semidry transferred proteins were applied to polyviny-
lidene diﬂuoride membranes. Nonspeciﬁc binding sites were blocked
overnight with 5% BSA in 20 mM Tris-HCl (pH 7.6), 140 mM NaCl,
and 0.1% Tween 20. Blots were probed for 1 h with rabbit polyclonal
anti-human phospho-CREB (ser 133) or CREB antibodies (1/2,000
dilution). These antibodies also recognize activating transcription
factor-1 (ATF-1), which belongs to the CREB family. After washing,
the immunoreactive bands were visualized using a peroxidase-
conjugated goat anti-rabbit immunoglobulin G (IgG) (1/10,000
dilution) antibody and an ECL Plus Western Blotting Detecting
System (Amersham Biosciences). Quantiﬁcations were carried out
using the Image J software and were expressed as arbitrary units.
cAMP, PGE2, and IL-8 enzyme immunoassays. cAMP concentra-
tions were measured in disrupted cells using a speciﬁc enzyme
immunoassay kit purchased from Cayman Chemical Co; the concen-
trations were measured after incubating AMs with LPS and/or ET for
30 min or 24 h. Protein concentrations were measured in cell lysates
using a kit from Pearce, and then the concentrations of cAMP were
expressed in picomoles per milligram of protein. IL-8 and PGE2
concentrations were measured in culture medium after 24 h
incubation of AMs with LPS and/or ET; these concentrations were
measured using a speciﬁc PGE2 enzyme immunoassay (Cayman
Chemical Co) and human IL-8 Kit DuoSet ELISA (R&D Systems),
which cross-reacts with guinea pig IL-8 [40].
PKA and sPLA2-IIA activity assays. AMs were incubated with LPS
and/or ET for 2 h. The PKA activity was then measured in disrupted
cells using a speciﬁc enzyme immunoassay kit purchased from
Promega. sPLA2-IIA activity was measured in culture medium using
[
3H]-oleic acid-labeled membranes of Escherichia coli, following a
modiﬁcation [41] of the method by Franson et al. [42].
Plasmid constructions and transfection. Mutated constructs [ 488;
þ46]-sPLA2-Luc were prepared, as described previously [43]. CHO
cells were seeded on dishes cultured in HAM F12, supplemented with
10% (v/v) FCS (Gibco BRL), 4 mM glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin. CHO cells were seeded in 24-well plates at a
concentration of 2.10
4 cells per plate at 70% conﬂuence, 24 h before
transfection. Transfections with mutated constructs [ 488; þ46]-
sPLA2-Luc, CREB, and DN CREB were performed using 0.75 ml of
LIPOFECTAMINE Plus (Invitrogen), 0.4 mg of reporter DNA, as
indicated in Figure 4, and 0.1 mg of pCMV-b-galactosidase per well.
The cells were incubated with HAM-F12 medium 3 h after adding the
DNA, and incubation was continued for 24 h. CHO cells were
incubated with PA (1 lg/ml) and EF (500 ng/ml) for 1 h. LPS (1 lg/ml)
was then added, and incubation was continued for an additional 24 h.
Luciferase activity was measured using a luciferase reporter assay kit,
with signal detection for 12 s by a luminometer (Berthold), and was
normalized by dividing the relative light units by b-galactosidase
activity [43]. The degree of induction was calculated relative to the
control.
Control of cell viability. Cell viability was checked by the trypan
blue dye exclusion test. Cell lysis was controlled by measuring the
release of lactate dehydrogenase (LDH) activity using a commercial
kit from Boehringer. No cell mortality was observed in all the
experiments presented in this study.
Statistical analysis. Data are expressed as the mean 6 standard
error of the mean (S.E.M.) of at least three separate experiments, and
statistical analyzes were performed using the unpaired Student t-test.
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